GENE ONLINE|News &
Opinion
Blog

2021-10-08| Special

Landmark CRISPR Trial Shows Promise Against Fighting Blindness, but Is It a Cure?

by Isha Kapoor
Share To
Cambridge, MA-based, leading genome editing biotech company, Editas Medicine, recently announced encouraging clinical data in the world's first attempt to use the CRISPR gene editing tool to treat blindness.

Preliminary results from the open-label Phase1/2 BRILLIANCE clinical trial of its investigational CRISPR-based experimental medicine, EDIT-101, have rekindled hope for the patients suffering from blindness due to Leber congenital amaurosis 10 (LCA10).

The safety and efficacy assessments were presented at the XIXth International Symposium on Retinal Degeneration (RD2021) on September 29th.

GO Prime with only $1.49 now

LATEST
An Interview with the Inventor of HPV Vaccine, Ian Frazer, Building a Firewall for Public Health
2024-02-29
Taiwan’s Drug Price Adjustments: Balancing Cost and Availability
2024-02-28
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
EVENT
Scroll to Top